Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CORT Corcept Therapeutics
24.320-0.150-0.61%
Close
02/03 16:00 ET
24.3200.0000.00%
Post Mkt Price 02/03 16:04 ET
High
24.870
Open
24.370
Turnover
14.89M
Low
23.930
Pre Close
24.470
Volume
611.79K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Estimating The Fair Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Corcept Therapeutics Incorporated (NASDAQ:CORT) as an investment opportunity by estimating the company
Corcept Therapeutics (NASDAQ:CORT) Downgraded by StockNews.com to "Buy"
StockNews.com downgraded shares of Corcept Therapeutics (NASDAQ:CORT – Get Rating) from a strong-buy rating to a buy rating in a research report report published on Monday morning. Separately, HC Wai
Stock Analysts' Downgrades for January 30th (ADM, BAH, BBSI, BMI, BSET, CDW, CORT, DEO, EW, HBAN)
Stock Analysts' downgrades for Monday, January 30th: Archer-Daniels-Midland (NYSE:ADM) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating. Get Archer-Daniels-Midla
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating)'s share price fell 4.9% on Tuesday . The company traded as low as $22.99 and last traded at $22.99. 349,104 shares changed hands during mi
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics (NASDAQ:CORT) Lowered to "Buy" at StockNews.com
Corcept Therapeutics (NASDAQ:CORT – Get Rating) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Tuesday. Separatel
Hussman Strategic Advisors Inc. Sells 15,500 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Hussman Strategic Advisors Inc. reduced its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) by 11.1% in the 3rd quarter, according to its most recent filing with t
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Unfortunately, these high risk investments
Robeco Institutional Asset Management B.V. Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)
Robeco Institutional Asset Management B.V. lessened its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) by 15.6% during the third quarter, according to the company
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. cut its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) by 15.6% in the third quarter, according to its most recent disc
Company Overview
More
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
CEO： Dr. Joseph K. Belanoff, M.D.
Market： NASDAQ
Listing Date： 04/14/2004
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet